In accordance with the World Health Organization, India accounts for one-fifth of cardiovascular deaths worldwide, especially in the younger population. The results of Global Burden of Disease study state the age-standardized CVD death rate of 272 per 100000 population in India which is much higher than that of the global average of 235.
Mortality associated with CAD in Asian Indians is 20–50% higher than any other population.The country’s success in tackling its diabetes and hypertension epidemic will be crucial to achieving Sustainable Development Goals globally.
At Lloyd, we are proud to be part of the mission of tackling the diabetes & hypertension epidemic with our quality medicines hence cardiology & diabetology are our focus areas.Our focus is on improving patient outcomes either by addressing unmet medical needs or by enhancing patient convenience and patient compliance through differentiated dosage forms.
Our portfolio includes Angiotensin receptor blockers, Calcium channel blockers, Beta-blockers, Anti-anginal, Anti-arrhythmic, Statins, Anti-coagulants and Diuretic combinations.
Our portfolio of anti-diabetic products includes oral anti-diabetic medication such as SGLT2 inhibitors, DPP4 inhibitors, Sulphonylureas in primary and secondary diabetes care management.